The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Eddy, 1996, A manual for assessing health practices and designing practice guidelines, 1

Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD

Vuppalanchi, 2009, Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: selected practical issues in their management, Hepatology, 49, 306, 10.1002/hep.22603

Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x

Neuschwander-Tetri, 2010, Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites, Hepatology, 52, 774, 10.1002/hep.23719

Targher, 2010, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease, N Engl J Med, 363, 1341, 10.1056/NEJMra0912063

, 2011, Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, Annals of Medicine, 43, 617, 10.3109/07853890.2010.518623

Musso, 2010, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease, Hepatology, 52, 79, 10.1002/hep.23623

Suzuki, 2005, Chronological development of elevated aminotransferases in a nonalcoholic population, Hepatology., 41, 64, 10.1002/hep.20543

Hamaguchi, 2005, The metabolic syndrome as a predictor of non-alcoholic fatty liver disease, Ann Intern Med, 143, 722, 10.7326/0003-4819-143-10-200511150-00009

Whalley, 2007, Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs, Clin Med., 7, 119, 10.7861/clinmedicine.7-2-119

Lee, 2007, Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center, J Hepatol., 47, 239, 10.1016/j.jhep.2007.02.007

Marcos, 2000, Transplantation, 69, 2410, 10.1097/00007890-200006150-00034

Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038

Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology., 40, 1387, 10.1002/hep.20466

Boza, 2005, Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass, Obes Surg., 15, 1148, 10.1381/0960892055002347

Haentjens, 2009, Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics, Acta Clin Belg., 64, 483, 10.1179/acb.2009.084

Machado, 2006, Hepatic histology in obese patients undergoing bariatric surgery, J Hepatol., 45, 600, 10.1016/j.jhep.2006.06.013

Colicchio, 2005, Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy, Ann Nutr Metab., 49, 289, 10.1159/000087295

Beymer, 2003, Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery, Arch Surg., 138, 1240, 10.1001/archsurg.138.11.1240

Leite, 2009, Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus, Liver Int., 29, 113, 10.1111/j.1478-3231.2008.01718.x

Prashanth, 2009, Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus, J Assoc Physicians India., 57, 205

Assy, 2000, Fatty infiltration of liver in hyperlipidemic patients, Dig Dis Sci, 1929, 10.1023/A:1005661516165

Li, 2009, Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China, Hepatobiliary Pancreat Dis Int., 8, 377

Amarapurkar, 2007, Prevalence of non-alcoholic fatty liver disease: population based study, Ann Hepatol., 6, 161, 10.1016/S1665-2681(19)31922-2

Park, 2006, Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults, J Gastroenterol Hepatol., 21, 138, 10.1111/j.1440-1746.2005.04086.x

Frith, 2009, Non-alcoholic fatty liver disease in older people, Gerontology., 55, 607, 10.1159/000235677

Chen, 2007, Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan, J Gastroenterol Hepatol., 22, 1482, 10.1111/j.1440-1746.2006.04615.x

Ong, 2008, Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease, J Hepatol., 49, 608, 10.1016/j.jhep.2008.06.018

Hashimoto, 2005, The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease, Hepatol Res., 33, 72, 10.1016/j.hepres.2005.09.007

Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology., 129, 113, 10.1053/j.gastro.2005.04.014

Chen, 2008, Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease, J Zhejiang Univ Sci B., 9, 616, 10.1631/jzus.B0720016

Clark, 2003, The prevalence and etiology of elevated aminotransferase levels in the United States, Am J Gastroenterol., 98, 960, 10.1111/j.1572-0241.2003.07486.x

Kallwitz, 2008, Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides, Dig Dis Sci., 53, 1358, 10.1007/s10620-008-0234-x

Wagenknecht, 2009, Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort, Obesity, 17, 1240, 10.1038/oby.2009.4

Fischer, 2009, Chronic liver disease among Alaska-Native people, 2003-2004, Am J Gastroenterol., 104, 363, 10.1038/ajg.2008.57

Bialek, 2008, Chronic liver disease among two American Indian patient populations in the southwestern United States, 2000-2003, J Clin Gastroenterol., 42, 949, 10.1097/MCG.0b013e318054492a

Matteoni, 1999, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology., 116, 1413, 10.1016/S0016-5085(99)70506-8

Dam-Larsen, 2004, Long term prognosis of fatty liver: risk of chronic liver disease and death, Gut., 53, 750, 10.1136/gut.2003.019984

Ekstedt, 2006, Long-term follow-up of patients with NAFLD and elevated liver enzymes, Hepatology., 44, 865, 10.1002/hep.21327

W, 2008, Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-based Cohort Study, Am J of Gastroenterology, 103, 2263, 10.1111/j.1572-0241.2008.02034.x

N, 2009, Long-Term Follow-Up of Patients with Non-Alcoholic Fatty Liver, Clinical Gastro and Hepatology, 7, 234, 10.1016/j.cgh.2008.11.005

Dam-Larsen, 2009, Final results of a long-term, clinical follow-up in fatty liver patients, Scand J Gastroenterol., 44, 1236, 10.1080/00365520903171284

M, 2010, Components of metabolic syndrome as independent predictors of mortality in chronic liver disease: A population-based study, Gut., 59, 1410, 10.1136/gut.2010.213553

Söderberg, 2010, Decreased survival of subjects with elevated liver function tests during a 28-year follow-up, Hepatology., 51, 595, 10.1002/hep.23314

Caldwell, 2004, The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease, J Hepatol., 40, 578, 10.1016/j.jhep.2004.02.013

Browning, 2004, Ethnic differences in the prevalence of cryptogenic cirrhosis, Am J Gastroenterol., 99, 292, 10.1111/j.1572-0241.2004.04059.x

Bugianesi, 2002, Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma, Gastroenterology., 123, 134, 10.1053/gast.2002.34168

Hashimoto, 2009, hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, J Gastroenterol., 44, 89, 10.1007/s00535-008-2262-x

Smedile, 2005, Steatosis and hepatocellular carcinoma risk, Eur Rev Med Pharmacol Sci., 9, 291

Takuma, 2010, Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review, World J Gastroenterol., 16, 1436, 10.3748/wjg.v16.i12.1436

Ascha, 2010, The incidence and risk factor of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 51, 1972, 10.1002/hep.23527

Yasui, 2011, Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma, Clin Gastroenterol Hepatol, 9, 428, 10.1016/j.cgh.2011.01.023

Hui, 2003, Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C, Hepatology, 38, 420, 10.1053/jhep.2003.50320

Sanyal, 2006, Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C, Hepatology, 42, 132

Yatsuji, 2009, Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C, J Gastroenterol Hepatol, 24, 248, 10.1111/j.1440-1746.2008.05640.x

Bhala, 2011, The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis. An international collaborative study, Hepatology, 54, 1208, 10.1002/hep.24491

Sanyal, 2011, End points and clinical trial design for nonalcoholic steatohepatitis, Hepatology, 54, 344, 10.1002/hep.24376

Liagnpunsakul, 2012, What do we recommend our patients with NAFLD about alcohol consumption?, Am J Gastroenterol

Struben, 2000, Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds, Am J Med, 108, 9, 10.1016/S0002-9343(99)00315-0

Willner, 2001, Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease, Am J Gastroenterol, 96, 2957, 10.1111/j.1572-0241.2001.04667.x

Abdelmalek, 2006, Familial aggregation of insulin resistance in first-degree delatives of patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 4, 1162, 10.1016/j.cgh.2006.06.001

Schwimmer, 2009, Heritability of nonalcoholic fatty liver disease, Gastroenterology, 136, 1585, 10.1053/j.gastro.2009.01.050

Kowdley, 2010, The role of iron in nonalcoholic fatty liver disease: the story continues, Gastroenterology, 138, 817, 10.1053/j.gastro.2010.01.023

Bacon, 2011, Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases, Hepatology, 54, 328, 10.1002/hep.24330

Vuppalanchi, 2011, Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network, Hepatol Int

Marchesini, 2003, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, Hepatology, 37, 917, 10.1053/jhep.2003.50161

Kang, 2006, Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD, Am J Gastroenterol, 101, 2247, 10.1111/j.1572-0241.2006.00719.x

Ryan, 2005, Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease, Diabetes Care, 28, 1222, 10.2337/diacare.28.5.1222

Wieckowska, 2006, In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease, Hepatology, 44, 27, 10.1002/hep.21223

Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496

Wieckowski, 2007, Noninvasis diagnosis and monitoring of nonalcoholic steatohepatitis: present and future, HEPATOLOGY, 46, 582, 10.1002/hep.21768

Andersen, 1991, Hepatic effects of dietary weight loss in morbidly obese subjects, J Hepatol., 12, 224, 10.1016/0168-8278(91)90942-5

Palmer, 1990, Effect of weight reduction on hepatic abnormalities in overweight patients, Gastroenterology., 99, 1408, 10.1016/0016-5085(90)91169-7

Park, 1995, Effect of weight control on hepatic abnormalities in obese patients with fatty liver, J Korean Med Sci., 10, 414, 10.3346/jkms.1995.10.6.414

Ueno, 1997, Therapeutic effects of restricted diet and exercise in obese patients with fatty liver, J Hepatol., 27, 103, 10.1016/S0168-8278(97)80287-5

Kugelmas, 2003, Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E, Hepatology, 38, 413, 10.1053/jhep.2003.50316

Sreenivasa Baba, 2006, Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis, J Gastroenterol Hepatol., 21, 191, 10.1111/j.1440-1746.2005.04233.x

Hickman, 2004, Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life, Gut., 53, 413, 10.1136/gut.2003.027581

Suzuki, 2005, Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease, J Hepatol, 43, 1060, 10.1016/j.jhep.2005.06.008

Tiikkainen, 2003, Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content, Diabetes, 52, 701, 10.2337/diabetes.52.3.701

Tamura, 2005, Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients, J Clin Endocrinol Metab., 90, 3191, 10.1210/jc.2004-1959

Westerbacka, 2005, Dietary fat content modifies liver fat in overweight nondiabetic subjects, J Clin Endocrinol Metab., 90, 2804, 10.1210/jc.2004-1983

Petersen, 2005, Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes, Diabetes., 54, 603, 10.2337/diabetes.54.3.603

Larson-Meyer, 2006, Effect of calorie restriction with or without exercise on insulin sensitivity, □-cell function, fat cell size, and ectopic lipid in overweight subjects, Diabetes Care, 29, 1337, 10.2337/dc05-2565

Thomas, 2006, Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease, World J Gastroenterol, 12, 5813, 10.3748/wjg.v12.i36.5813

Thamer, 2007, High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention, Obesity, 15, 531, 10.1038/oby.2007.568

Schafer, 2007, Lifestyle intervention in individuals with normal versus impaired glucose tolerance, Eur J Clin Invest, 37, 535, 10.1111/j.1365-2362.2007.01820.x

Cowin, 2008, Magnetic resonance imaging and spectroscopy for monitoring liver steatosis, J Magn Reson Imaging, 28, 937, 10.1002/jmri.21542

Larson-Meyer, 2008, Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function, Obesity, 16, 1355, 10.1038/oby.2008.201

Viljanen, 2009, Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance, J Clin Endocrinol Metab, 94, 50, 10.1210/jc.2008-1689

Kantartzis, 2009, High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease, Gut, 58, 1281, 10.1136/gut.2008.151977

Kirk, 2009, Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction, Gastroenterology, 136, 1552, 10.1053/j.gastro.2009.01.048

Lazo, 2010, Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes, Diabetes Care, 33, 2156, 10.2337/dc10-0856

Wang, 2003, Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review, Am J Med., 115, 554, 10.1016/S0002-9343(03)00449-2

Hickman, 2002, Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C, Gut, 51, 89, 10.1136/gut.51.1.89

Huang, 2005, One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study, Amer J Gastroenterol., 100, 1072, 10.1111/j.1572-0241.2005.41334.x

Tendler, 2007, The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study, Digestive Diseases & Sciences., 52, 589, 10.1007/s10620-006-9433-5

Zelber-Sagi, 2006, A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol., 4, 639, 10.1016/j.cgh.2006.02.004

Harrison, 2009, Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial, Hepatology, 49, 80, 10.1002/hep.22575

Promrat, 2010, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, 51, 121, 10.1002/hep.23276

Shojaee-Moradie, 2007, Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism, Diabetologia, 50, 404, 10.1007/s00125-006-0498-7

Bonekamp, 2008, The effects of an exercise training intervention on hepatic steatosis [Abstract], Hepatology, 48, 806A

Johnson, 2009, Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss, Hepatology, 50, 1105, 10.1002/hep.23129

van der Heijden, 2010, A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents, Obesity, 18, 384, 10.1038/oby.2009.274

Marchesini, 2001, Metformin in non-alcoholic steatohepatitis, Lancet., 358, 893, 10.1016/S0140-6736(01)06042-1

Uygun, 2004, Metformin in the treatment of patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther., 19, 537, 10.1111/j.1365-2036.2004.01888.x

Nair, 2004, Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial, Aliment Pharmacol Ther., 20, 23, 10.1111/j.1365-2036.2004.02025.x

Bugianesi, 2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol., 100, 1082, 10.1111/j.1572-0241.2005.41583.x

Loomba, 2009, Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 29, 172, 10.1111/j.1365-2036.2008.03869.x

Shields, 2009, The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot study, Therap Adv Gastroenterol, 2, 157, 10.1177/1756283X09105462

Haukeland, 2009, Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial, Scand J Gastroenterol, 44, 853, 10.1080/00365520902845268

Idilman, 2008, Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 28, 200, 10.1111/j.1365-2036.2008.03723.x

Duseja, 2007, Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions, Ann Hepatol, 6, 222, 10.1016/S1665-2681(19)31902-7

Nar, 2009, The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease, Acta Diabetol., 46, 113, 10.1007/s00592-008-0067-2

Omer, 2010, Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease, European J Gastroenterol Hepatology., 22, 18, 10.1097/MEG.0b013e32832e2baf

Neuschwander-Tetri, 2003, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone, Hepatology., 38, 1008, 10.1053/jhep.2003.50420

Ratziu, 2008, Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial, Gastroenterology, 135, 100, 10.1053/j.gastro.2008.03.078

Ratziu, 2010, Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology, 51, 445, 10.1002/hep.23270

Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med., 355, 2297, 10.1056/NEJMoa060326

Aithal, 2008, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis, Gastroenterology, 135, 1176, 10.1053/j.gastro.2008.06.047

Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929

Lincoff, 2007, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials, JAMA, 298, 1180, 10.1001/jama.298.10.1180

Hasegawa, 2001, Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with nonalcoholic steatohepatitis: a pilot study, Aliment Pharmacol Ther, 15, 1667, 10.1046/j.1365-2036.2001.01083.x

Harrison, 2003, Vitamin E and vitamin C treatment improves fibrosis is patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 98, 2485, 10.1111/j.1572-0241.2003.08699.x

Dufour, 2006, Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 4, 1537, 10.1016/j.cgh.2006.09.025

Sanyal, 2004, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4

Yakaryilamz, 2007, Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis, results of a pilot study, Intern Med J, 37, 229, 10.1111/j.1445-5994.2006.01295.x

Bjelakovic, 2010, Meta-analysis: antioxidant supplements for liver disease - the Cochrane Hepato-Biliary Group, Aliment Pharmacol Ther, 32, 356, 10.1111/j.1365-2036.2010.04371.x

Lavine, 2011, Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial, JAMA., 305, 1659, 10.1001/jama.2011.520

Miller, 2005, Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality, Ann Intern Med, 142, 37, 10.7326/0003-4819-142-1-200501040-00110

Bjelakovic, 2007, Mortality in randomized trials of antioxidant supplements of primary and secondary prevention: systematic review and meta-analysis, JAMA., 297, 842, 10.1001/jama.297.8.842

Berry, 2009, Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality, Clin Trials, 6, 28, 10.1177/1740774508101279

Gerss, 2009, The questionable association of vitamin E supplementation and mortality - inconsistent results of different meta-analytic approaches, Cell Mol Biol, 55, 1111

Dietrich, 2009, Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role?, Atherosclerosis, 205, 549, 10.1016/j.atherosclerosis.2008.12.019

Klein, 2011, Vitamin E and the risk of prostate cancer, The selenium and vitamin E cancer prevention trial (SELECT). JAMA, 306, 1549

Laurin, 1996, Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic induced steatohepatitis: a pilot study, Hepatology, 23, 1464, 10.1002/hep.510230624

Leushner, 2010, High-dose Ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial, Hepatology, 52, 472, 10.1002/hep.23727

Lindor, 2004, Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology, 39, 770, 10.1002/hep.20092

Ratziu, 2011, A randomized controlled trial of hig-dose ursogeoxycholic acid for nonalcoholic steatohepatitis, J Hepatol, 54, 1011, 10.1016/j.jhep.2010.08.030

Capanni, 2006, Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study, Alimentary pharmacology & therapeutics, 23, 1143, 10.1111/j.1365-2036.2006.02885.x

Masterton, 2010, Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease, Alimentary pharmacology & therapeutics, 31, 679, 10.1111/j.1365-2036.2009.04230.x

Mathurin, 2009, Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced liver disease, Gastroenterology, 137, 532, 10.1053/j.gastro.2009.04.052

Mummadi, 2008, Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis, Clinical Gastro and Hepatol, 6, 1396, 10.1016/j.cgh.2008.08.012

Chavez-Tapia, 2010, Bariatric surgery for non-alcoholic steatohepatitis in obese patients, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007340.pub2

http://rethinkingdrinking.niaaa.nih.gov/IsYourDrinkingPatternRisky/WhatsAtRiskOrHeavyDrinking.asp

Dunn, 2008, Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease, Hepatology, 47, 1947, 10.1002/hep.22292

Gunji, 2009, Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population, Am J Gastroenterol, 104, 2189, 10.1038/ajg.2009.361

Suzuki, 2007, Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia, Am J Gastroenterol, 102, 1912, 10.1111/j.1572-0241.2007.01274.x

Moriya, 2011, Alcohol consumption appears to protect against non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 33, 378, 10.1111/j.1365-2036.2010.04520.x

Dixon, 2001, Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese, Gastroenterology, 121, 91, 10.1053/gast.2001.25540

Cotrim, 2009, Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients, Eur J Gastroenterol Hepatol, 21, 969, 10.1097/MEG.0b013e328328f3ec

Dunn, 2009, Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with nonalcoholic fatty liver disease (NAFLD), Hepatology, 50

Chatrath, 2012, Dyslipidemia in patients with nonalcoholic fatty liver disease, Seminars in Liver Disease, 32, 22, 10.1055/s-0032-1306423

Chalasani, 2004, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity, Gastroenterology, 128, 1287, 10.1053/j.gastro.2004.02.015

Vuppalanchi, 2005, Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes, Am J Med Sci, 329, 62, 10.1097/00000441-200502000-00002

Chalasani, 2005, Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease, Hepatology, 41, 690, 10.1002/hep.20671

Browning, 2006, Statins and hepatic steatosis: perspectives from the Dallas Heart Study, Hepatology, 44, 466, 10.1002/hep.21248

Lewis, 2007, Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial, Hepatology., 46, 1453, 10.1002/hep.21848

Horlander, 2001, Atorvastatin for the treatment of NASH, Gastroenterology, 120, 2767

Gomer-Dominguez, 2006, A pilot study of atorvastatin treatment in dyslipid, non-alcoholic fatty liver patients, Aliment Pharmacol Ther, 23, 1643, 10.1111/j.1365-2036.2006.02926.x

Antonopoulos, 2006, Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients, Atherosclerosis, 184, 233, 10.1016/j.atherosclerosis.2005.08.021

Foster, 2011, Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St. Francis Heart Study Randomized Clinical Trial, Am J Gastroenterol, 106, 71, 10.1038/ajg.2010.299

Athyros, 2006, Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study, Curr Med Res Opin, 22, 872, 10.1185/030079906X104696

Athyros, 2010, Lancet, 376, 1916, 10.1016/S0140-6736(10)61272-X

Ekstedt, 2007, Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study, J Hepatol, 47, 135, 10.1016/j.jhep.2007.02.013

Nelson, 2009, A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial, J Clin Gastroenterol, 43, 990, 10.1097/MCG.0b013e31819c392e

Brunt, 2003, Concurrence of histological features of steatohepatitis with other forms of chronic liver disease, Mod Pathol, 16, 49, 10.1097/01.MP.0000042420.21088.C7

Leandro, 2006, Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data, Gastroenterology, 130, 1636, 10.1053/j.gastro.2006.03.014

Petta, 2011, Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV, Liver Int, 31, 507, 10.1111/j.1478-3231.2011.02453.x

Eslam, 2011, Meta-analysis: insulin resistance and sustained virological response in hepatitis C, Alimen Pharmacol Ther, 34, 297, 10.1111/j.1365-2036.2011.04716.x

Sorrentino, 2010, Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis, J Gastroenterol, 45, 1053, 10.1007/s00535-010-0249-x

Romero-Gomez, 2005, Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients, Gastroenterology, 128, 636, 10.1053/j.gastro.2004.12.049

Reddy, 2008, Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin, J Viral Hepa, 15, 129, 10.1111/j.1365-2893.2007.00901.x

Negro, 2009, Impact of obesity, steatosis and insulin resistance on progression and response to therapy to hepatitis C, J Viral Hepat, 16, 681, 10.1111/j.1365-2893.2009.01186.x

Jacobson, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med, 364, 2405, 10.1056/NEJMoa1012912

Zeuzam, 2011, Telaprevir for retreatment of HCV infection, N Engl J Med, 364, 2417, 10.1056/NEJMoa1013086

Bacon, 2011, Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med, 364, 1207, 10.1056/NEJMoa1009482

Poordad, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, 1195, 10.1056/NEJMoa1010494

Sherman, 2011, Response-guided telaprevir combination treatment for hepatitis C virus infection, N Engl J Med, 365, 1014, 10.1056/NEJMoa1014463

Garcia-Tsao, 2007, Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis, Am J Gastroenterol, 102, 2086, 10.1111/j.1572-0241.2007.01481.x

Bruix, 2011, Management of Hepatocellular carcinoma: An update, Hepatology, 53, 1020, 10.1002/hep.24199

Schwimmer, 2006, Prevalence of fatty liver in children and adolescents, Pediatrics., 118, 1388, 10.1542/peds.2006-1212

Schwimmer, 2005, Histopathology of pediatric nonalcoholic fatty liver disease, Hepatology, 42, 641, 10.1002/hep.20842

Feldstein, 2009, The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years, Gut., 58, 1538, 10.1136/gut.2008.171280

Riley, 2005, Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists, J Pediatr., 147, 839, 10.1016/j.jpeds.2005.07.020

Patton, 2008, Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis (NASH), Gastroenterology, 135, 1961, 10.1053/j.gastro.2008.08.050

Barlow, 2007, Expert Committee Recommendations Regarding the Preventions, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report, Pediatrics, 120, S164, 10.1542/peds.2007-2329C

Loomba, 2009, Advances in pediatric nonalcoholic fatty liver disease, Hepatology., 50, 1282, 10.1002/hep.23119

Alkhouri, 2011, A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis, Clin Gastroenterol Hepatol., 9, 150, 10.1016/j.cgh.2010.09.015

Nobili, 2009, Performance oof ELF serum markers in predicting serum fibrosis stage in pediatric non-alcoholic fatty liver disease, Gastroenterology, 136, 160, 10.1053/j.gastro.2008.09.013

Kleiner, 2005, Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701

Carter-Kent, 2009, Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study, Hepatology., 50, 1113, 10.1002/hep.23133

Ko, 2009, Clinical and histological features of nonalcoholic fatty liver disease in children, Dig Dis Sci., 54, 2225, 10.1007/s10620-009-0949-3

Nobili, 2006, NAFLD in children: A prospective clinical-pathological study and effect of lifestyle, HEPATOLOGY, 458, 10.1002/hep.21262

Nobili, 2008, Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial, Hepatology, 48, 119, 10.1002/hep.22336

Barlow, 2002, Management of child and adolescent obesity: summary and recommendations based on reports from pediatricians, pediatric nurse practitioners, and registered dietitians, Pediatrics, 110, 236, 10.1542/peds.110.S1.236

Grundy, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation., 112, 2735, 10.1161/CIRCULATIONAHA.105.169404